Additional Information

Description

Renflexis® (Infliximab-Abda) 100 mg Injection is a biosimilar monoclonal antibody used for the treatment of autoimmune diseases. It contains 100 mg of lyophilized infliximab-abda in a 20 mL single-dose vial for intravenous infusion. The formulation targets tumor necrosis factor-alpha (TNF-a), a pro-inflammatory cytokine involved in chronic inflammatory conditions. By inhibiting TNF-a, the drug reduces inflammation and prevents disease progression in conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.

The mechanism of action involves binding to TNF-a, neutralizing its activity, and preventing interaction with TNF receptors on cell surfaces. This inhibition reduces inflammation, decreases immune system overactivity, and mitigates symptoms associated with autoimmune disorders. The biosimilar nature of Renflexis® ensures comparable efficacy, safety, and immunogenicity to the reference biologic infliximab.

Renflexis® is prescribed for patients who require long-term TNF inhibition to manage inflammatory diseases. Dosing schedules vary based on the condition being treated, typically involving an initial induction phase followed by maintenance doses. Patients receiving this therapy must be monitored for infusion reactions, infections, and immune-related adverse effects.